RESI San Francisco
January 10, 2023

(Virtual-Only Partnering, January 11-12)

8 AM – Angels and Family Offices
How Do Family Offices & Angels View Seed & Series A Rounds?

Angel investors are a mainstay in the earliest financing rounds, and many consider Family Offices as the holy grail of investors. These groups share many similarities, and can work in synergy to help their portfolio companies advance. This panel will cover topics such as:

  • What are the similarities and differences between Angels and Family Offices?
  • What are the benefits of working with each group?
  • How does investing personal money change the way Angels and Family Offices act from the traditional VC?

A startup looks to many different kinds of investors when fundraising, and understanding the fundamental differences between groups can improve the success of their approach. Angels and Family Offices frequently invest early on, and can shape the way a company develops. Panelists will discuss how best to approach them and engage their interest.


9 AM – Big Pharma
Strategies for Preclinical & Early Clinical Assets

In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This panel brings together speakers from various big pharma companies to discuss topics such as:

  • How big pharma sources assets
  • The evaluation and investment process
  • Key factors of interest
  • How early-stage big pharma is willing to look

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.


10 AM – Pitching Your AI to Investors
Strategies for Standing Out

AI is embedded in the tech of many life science startups, but are they utilizing it to stand out to investors? Hear from life science and tech investors on how early-stage founders can pitch their AI technology effectively. The right connection can start with a strong first impression, so learn how to bring your tech from pitch to partnership.


11 AM – Pediatrics
Advancing Treatments for Pediatric Patients

Since 2015, the US regulatory, public/private payor, and clinical research environments have implemented sweeping changes to the policies and requirements governing healthcare innovation targeting the pediatric patient population. Despite these changes, funding for pediatric innovation remains exponentially lower relative to the nature of the commitments being made to adult indications, especially troubling in light of nearly 40% of the world’s population will be under the age of 21, yet less than 15% of all healthcare investment is targeting pediatric indications. This panel will explore several topics including:

  • What are the specific gaps in pediatric patient engagement?
  • How and why are current novel treatments under development superior to historic care options?
  • What are the challenges that impact the efficiency, effectiveness, and successful commercialization of scientific innovations targeting the pediatric patient population?
  • What changes need to be made to incentivize and motivate global healthcare manufacturers to increase their pediatric healthcare R&D budgets respectively?

Panelists will discuss topics relevant to all areas of pediatric care and the importance of addressing an underserved population, and how improvements to pediatric care can save long-term costs for the healthcare industry long after these patients reach adulthood.

1 PM – Asia Cross Border
Building Global Partnerships

These days, seeking capital from Asia-headquartered investors, pharmaceuticals, and other strategic partners may seem like nothing new. Many groups continue to expand into geographies outside of Asia to set up new offices, establishing open innovation departments, etc. However, companies based in the USA, Europe, and other parts of the world without any proper connection to Asia still find themselves struggling to engage with the right groups. This panel will discuss the following topics and more:

  • How are Asian markets and regulatory hurdles different from those of the USA/Europe?
  • What do cross-border investors seek in companies outside of Asia? How are they similar or different to their viewpoint on domestic companies?
  • How has COVID positively or negatively impacted the decision making process?
  • Aside from the effects of COVID on the industry, will cross-border investment activities continue to increase?
  • What are some common mistakes investors see from entrepreneurs, and how can they be avoided?

Panelists will discuss how they have been evaluating opportunities in the midst of the COVID pandemic and what the future holds for cross-border activities in the industry. Panelists will also uncover general topics such as navigating the Asian market and the regulatory challenges associated with market entry, how to approach Asian investors and strategic groups, and more.


2 PM – Longevity Investment
Aging Innovation for a Better Future

This panel will feature investors that focus on longevity. Learn about their investment preferences and how they evaluate and manage their relationships with their early-stage portfolio and prospects in this specific market. Hear from active age-tech experts on their predictions for the future of this sector.


3 PM – Medtech Strategics
Large Corporations Seeking External Innovation in the MedTech Space

In the medical technology sector, major corporations are increasingly looking to external startups and inventors for innovative new technologies. In addition to traditional M&A, these major strategic players are exploring innovative strategies to partner with early stage startups, and our speakers will explore topics such as:

  • How do major corporations find new device technologies that are a fit for their pipelines?
  • What can an early stage startup do to find the right partner?
  • How do partnerships work, and what conditions might a major partner have?
  • What kind of technical and commercial validation will be required to secure a partnership?
  • The panelists will explore these topics with reference to the technology areas that they are looking at for their future pipelines.

4 PM – Corporate VC
The Changing Landscape & New Opportunities

Corporate venture capital firms are an important source of capital for early-stage companies. Many major pharmaceuticals and large corporations have set up a corporate investment arm to identify early-stage companies. Strategically and financially driven in varying degrees, the implications of working with CVCs are huge, as the resources, network, and guidance provided by the CVC and the associated parent company are incredibly valuable to an entrepreneur who is actively growing their business.

This panel will discuss the following topics and more:

  • How are CVCs different from traditional VCs?
  • How strategically vs. financially are CVCs driven, and how does this affect their decision-making process?
  • How closely does the CVC communicate with the parent company?
  • What does working with a CVC entail?

Panelists will discuss each of their investment mandates and how they relate to corporate interests, and how they have been sourcing opportunities during COVID. Panelists may also explore current trending areas of interest, and what they see as emerging fields in the near future.